Clinical Trials Logo

Anemia, Hemolytic clinical trials

View clinical trials related to Anemia, Hemolytic.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05711264 Not yet recruiting - Clinical trials for Autoimmune Hemolytic Anemia

Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.

Start date: January 30, 2023
Phase:
Study type: Observational

1. Study the presence of circulating CD4+/CD28 null T lymphocytes in AIHA either Idiopathic or Secondary. 2. Role of CD4+/CD28 null T lymphocytes in monitoring response to therapy in AIHA.

NCT ID: NCT04814394 Not yet recruiting - Clinical trials for Autoimmune Hemolytic Anemia

The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment

fhfr
Start date: April 1, 2022
Phase:
Study type: Observational

we study the circulating T-follicular regulatory and T-follicular regulatory cells in autoimmune hemolytic anemia.

NCT ID: NCT03533322 Not yet recruiting - Clinical trials for Gall Bladder Disease

Gall Bladder Status Among Children With Chronic Haemolytic Anemia

GBSACWCHA
Start date: October 1, 2018
Phase:
Study type: Observational

Gall bladder status among children with chronic haemolytic anemia attending to Assuit University Children Hospital. Hemolysis is defined as the premature destruction of red blood cells (RBCs) (a shortened RBC life span). Anemia results when the rate of destruction exceeds the capacity of the marrow to produce RBCs. Normal RBC survival time is 110-120 days (half-life: 55-60 days), and thus, approximately 0.85% of the most senescent RBCs are removed and replaced each day. Patients with chronic haemolytic anemia are subjected to many complications of chronic haemolytic anemia e.g anemic heart failure, complications of blood transfusion as hepatitis and AIDS, hypersplenism, haemosiderosis ,among them there is incidence of gallbladder stone formation. This work aims to a) to determine the prevalence of gall bladder diseases among patient with chronic haemolytic anemia. b) to determine the risk factors of gall bladder diseases among patients with chronic haemolytic anemia.